RxDoctor Payments Data

Kushal Naha, MD

Hematology · Fort Wayne, INNPI 1639586506

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (40.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Roche Molecular Systems, Inc. at 53.6% of the total. Reporting peaked in 2024 at $4,100 and has fallen 88.5% since, to $470 in 2025.

$6,535in general payments, 2019–2025

Across 60 payments — averaging $108.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche Molecular Systems, Inc.$4K
  • Sanofi$298
  • Incyte Corporation$291
  • AVEO Pharmaceuticals, Inc.$205
  • Pfizer$198
  • Dendreon Pharmaceuticals LLC$153
  • plus $2K from 31 others
$31,869in research payments, 2019–2025

Across 1 payment — averaging $31,869 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$32K

What the payments were for

  • Speaking & faculty fees$1,70026%
  • Travel & lodging$1,80528%
  • Food & beverage$2,64841%
  • Education$3836%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$80,403
Medicare patients
264
Services billed
1,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate34$834,322
XtandiEnzalutamide46$659,237
RevlimidLenalidomide26$486,552
Lenalidomide32$480,399
NubeqaDarolutamide38$478,419
FotivdaTivozanib Hcl14$391,226
Abiraterone Acetate188$343,341
LynparzaOlaparib21$239,061
DopteletAvatrombopag Maleate12$101,297
NeulastaPegfilgrastim11$70,959
EliquisApixaban66$61,686
XareltoRivaroxaban17$13,448
OxycontinOxycodone Hcl11$3,746
Ondansetron Hcl52$2,708
Oxycodone Hcl82$1,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$20$834,32234 claims
Astellas Pharma US IncXtandi$35$659,23746 claims
AstraZenecaLynparza$18$239,06121 claims
PfizerEliquis$198$61,68666 claims
Johnson & JohnsonXarelto$47$13,44817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Indianaon file to place this against a meaningful peer group, so we don't.

Other hematology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →